the National Psoriasis Foundation (NPF) has appointed a female chair of its medical board.

For the first time in its 46-year history, the National Psoriasis Foundation (NPF) – the world’s largest nonprofit organization serving people with psoriasis and psoriatic arthritis – has appointed a female chair of its medical board. The Psoriasis Foundation selected dermatologist Dr. Abby Van Voorhees to this honor for her two decades of expertise and dedication in psoriatic disease care and research.

Read more...

Cherie Dobbs|Aesthetician, Formulator, and Educator

Cherie Dobbs grew up in Newport Beach, California. At the age of 10, Dobbs knew that she wanted to be connected to the aesthetic industry. Inspired by her mom, a hairdresser, Dobbs would ride her bike after school and visit her mom at the salon. She loved going to the salon to help clean and listen to all the women talk about their concerns. Occasionally,…

Read more...

Circadia is excited to announce the launch of its new website.

Circadia is excited to announce the launch of its new website. The website’s homepage welcomes customers with bold colors, a clean, uncluttered design, and featured content focused on the company’s mission to provide customers the most accurate product information, strengthen partner relations and share Dr. Pugliese’s knowledge and expertise in the skin care field.

Read more...

Suneva Medical, Inc. recently announced that it has amended its existing licensing agreement with Histogen, Inc

Suneva Medical, Inc. recently announced that it has amended its existing licensing agreement with Histogen, Inc. Under the terms of the amended agreement, Suneva Medical is the exclusive licensee for the distribution of the Regenica® skin care line through the physician-dispensed channel in Europe, most of Asia, South America, Canada, Australia, and the Middle East.

Read more...

FDA recently announced that it had granted a first-ever approval of a combination treatment for melanoma

The United States Food and Drug Administration (FDA) recently announced that it had granted a first-ever approval of a combination treatment for melanoma, the most deadly type of skin cancer. The agency approved the combination of GlaxoSmithKline’s genetically-targeted dabrafenib (Tafinlar™) and trametinib (Mekinist™) for patients with metastatic or unresectable melanoma whose tumors possess either the BRAF V600E or V600K genetic mutations.

Read more...

February 2024

Brands of the Month

  • Eminence Organic Skin Care
  • DMK Skin Revision Center
  • Repechage

Trending Industry News